Skip to Content

Clinical Trial Details

Sunitinib Use After Chemotherapy

Randomized Phase III, Double-Blind Placebo Controlled Trial of Sunitinib as Maintenance Therapy in Non-progressing Patients Following an Initial Four Cycles of Platinum-based Combination Chemotherapy in Advanced Stage IIIB/IV NSCLC


Patients with advanced stage IIIB/IV non-small cell lung cancer may be eligible for this study. Patients will be randomized to receive either Sunitinib or placebo after standard chemotherapy to see if Sunitinib helps their tumor shrink or stop growing.

IRB Protocol Number
CALGB 30607
Principal Investigator(s)
Charles Catcher, MD

Clinical Trial Categories

  • Lung Cancer
National Cancer Institute
Barbara Beauchemin, RN, BSN at 603-224-2556


  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000